Prestigious Award Provides Non-Dilutive Funding to Support Preclinical Activities Designed to Enable Translational Studies and Advancement into Clinical Development of First-in-Class GPR35 Inhibitors

着名的奖项提供非稀释资金来支持临床前活动，旨在促进转化研究并推进一流GPR35抑制剂的临床开发

OXFORD, England, Sept. 13, 2023 /PRNewswire/ -- ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today announced that the company has been awarded a highly competitive Biomedical Catalyst (BMC) grant from Innovate UK, the UK's innovation agency.

英国牛津，2023年9月13日/PRNewswire/-ThirtyFiveBio Limited，一家生物技术公司，开发一流的G蛋白偶联受体35（GPR35）小分子抑制剂，用于治疗胃肠道（GI）疾病，今天宣布该公司已获得英国创新机构Innovate UK的高竞争力生物医学催化剂（BMC）资助。

The grant, for a total of £495,000 (~$625,000), will fund research designed to enable the company to conduct translational studies of first-in-class GPR35 inhibitors for the treatment of gastrointestinal inflammatory diseases and cancers, ultimately allowing for the advancement of those compounds into clinical development..

该赠款总额为495000英镑（约625000美元），将资助旨在使该公司能够进行一流的GPR35抑制剂转化研究，用于治疗胃肠道炎症性疾病和癌症，最终实现进步这些化合物进入临床开发。。

The project is focused on optimising first-of-their-kind rodent-GPR35 antagonist small molecules to support preclinical evaluation of opportunities for GPR35 inhibitors in clinically translational murine models of disease. This effort will result in a critically needed research tool capable of addressing the fact that human GPR35 inhibitors do not cross-react with rodent-GPR35 receptors and therefore cannot be deployed to many animal models of disease.

该项目的重点是优化首例啮齿动物GPR35拮抗剂小分子，以支持临床转化小鼠疾病模型中GPR35抑制剂机会的临床前评估。这项努力将产生一个急需的研究工具，能够解决人类GPR35抑制剂不与啮齿动物GPR35受体交叉反应的事实，因此不能部署到许多动物疾病模型。

The resulting small molecules will be essential in defining clinical scope of human-GPR35 inhibitors and enabling advancement of clinical candidates to proof-of-concept studies in humans..

由此产生的小分子对于确定人类GPR35抑制剂的临床范围以及使临床候选人的进步能够在人类中进行概念验证研究至关重要。。

'We believe that GPR35 inhibition represents an extremely promising and novel therapeutic approach to addressing GI cancers and inflammatory diseases, many of which need new therapies that can deliver durable results with improved tolerability. As a company at the forefront of research in this emerging area, one of our focuses is creating innovative preclinical tools for evaluating, optimising and advancing the most promising GPR35 inhibitors.  Our work in this area will be significantly advanced by the grant funding received from Innovate UK and we would like to express our deep gratitude to the agency for recognizing the value of this project and providing the BMC grant,' said James Westcott, Ph.D., chief executive officer of ThirtyFiveBio..

'我们相信GPR35抑制代表了一种非常有前途和新颖的治疗方法来解决胃肠癌和炎症性疾病，其中许多需要新的疗法，可以提供持久的结果，提高耐受性。作为处于这一新兴领域研究前沿的公司，我们的重点之一是创建创新的临床前工具，用于评估，优化和推进最有希望的GPR35抑制剂。James Westcott博士说，我们在这方面的工作将通过Innovation UK获得的赠款资金得到显着推进，我们对该机构认识到该项目的价值并提供BMC赠款表示深深的感谢。.ThirtyFiveBio首席执行官。。

The role of GPR35 in GI diseases is genetically validated with several drug developers advancing programs designed to address the target. To date, virtually all these efforts have been focused on increasing the activity of GPR35 with targeted agonists. However, important recent scientific findings, including key insights from the ThirtyFiveBio team, support the hypothesis that GPR35 antagonism may represent a more appropriate therapeutic approach by blocking unwanted GPR35 signaling.

GPR35在胃肠道疾病中的作用通过几位药物开发者推进旨在解决该目标的计划进行了基因验证。迄今为止，几乎所有这些努力都集中在用靶向激动剂增加GPR35的活性上。然而，最近重要的科学发现，包括来自三十五岁生物团队的重要见解，支持GPR35拮抗作用可能通过阻断不需要的GPR35信号传导代表更合适的治疗方法的假设。

Based on this evolved scientific perspective, supported by the company's work with several world-leading, academic GPR35 specialists, ThirtyFiveBio is uniquely pursuing antagonism of the target with first-in-class small molecule GPR35 inhibitors..

基于这种不断发展的科学观点，在该公司与几位世界领先的学术GPR35专家合作的支持下，三十五岁的生物正在独特地追求一流的小分子GPR35抑制剂对靶点的拮抗作用。。

Supporting the company's focus on GPR35 inhibition is a collection of pre-clinical data generated by its scientists that highlights the association between GPR35 mutations and GI diseases. This includes research showing that GPR35 variants are linked to inflammatory bowel disease, and that GPR35 expression is upregulated in GI cancers.

支持该公司关注GPR35抑制的是其科学家生成的一系列临床前数据，突出了GPR35突变与胃肠道疾病之间的关联。这包括研究显示GPR35变体与炎症性肠病相关，并且GPR35表达在GI癌症中上调。

The company has also shown that pathogenic mutations of GPR35 drive its increased expression and function. Furthermore, study results have demonstrated that commonly dysregulated GI-cancer genes can be reversed by knocking out GPR35 in cancer cells. Taken together, these findings provide compelling evidence that hyperactive genetic mutations within GPR35 contribute to a range of GI disease processes, and that inhibiting GPR35 activity may have therapeutic utility in these diseases.  .

该公司还表明，GPR35的致病性突变驱动其表达和功能增强。此外，研究结果表明，通过敲除癌细胞中的GPR35可以逆转通常失调的GI癌基因。综上所述，这些发现提供了令人信服的证据，表明GPR35内的过度活跃的基因突变有助于一系列GI疾病过程，并且抑制GPR35活性可能在这些疾病中具有治疗效用。  .

About ThirtyFiveBio

About ThirtyFiveBio

ThirtyFiveBio Limited is a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease. The company has built scientific thought leadership in the biology of GPR35 and the role that it plays in GI disease, including digestive tract cancers.

ThirtyFiveBio Limited是一家生物技术公司，开发G蛋白偶联受体35（GPR35）的一流小分子抑制剂，用于治疗胃肠道（GI）疾病。该公司在GPR35的生物学及其在胃肠道疾病（包括消化道癌）中发挥的作用方面建立了科学思想领导地位。

ThirtyFiveBio has leveraged its fully enabled drug discovery platform to identify multiple unique families of first-in-class small-molecule GPR35 inhibitors that it is advancing through lead optimization activities. Created by M:M Bio and Canaan Partners, the company has raised $20 million in seed financing to date.

ThirtyFiveBio利用其完全启用的药物发现平台来识别多个独特的一流小分子GPR35抑制剂家族，这些家族正在通过铅优化活动推进。该公司由M:M Bio和Canaan合作伙伴创建，迄今已筹集2000万美元的种子融资。

ThirtyFiveBio is headquartered at the Innovation Centre on Milton Park, a key science precinct south of Oxford, UK. For more information, please visit: www.30fivebio.com.

ThirtyFiveBio总部设在英国牛津南部重点科学区Milton Park创新中心。欲了解更多信息，请访问：www.30fivebio.com。

About Innovate UK

关于创新英国

Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas. We connect businesses to the partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth. We fund business and research collaborations to accelerate innovation and drive business investment into R&D.

创新英国通过支持企业发展和实现新思想的潜力来推动生产力和经济增长。我们将业务与合作伙伴，客户和投资者联系起来，以帮助他们将想法转化为商业上成功的产品和服务以及业务增长。我们资助业务和研究合作，加速创新，推动企业投资研发。

Our support is available to businesses across all economic sectors, value chains and UK regions. Innovate UK is part of UK Research and Innovation. For more information visit  https://www.ukri.org/councils/innovate-uk/.

我们的支持适用于所有经济部门，价值链和英国地区的企业。Innovate UK是英国研究与创新的一部分。欲了解更多信息，请访问https://www.ukri.org/councils/innovate-uk/.

Contacts:ThirtyFiveBio            James WestcottChief Executive Officer P: +44 (0)1235 644980 [email protected]

联系人：ThirtyFiveBio James Westcott首席执行官P:+44（0）1235 644980[电子邮件保护]

Vida Strategic Partners (on behalf of ThirtyFiveBio)Tim Brons (Media)415-675-7402 [email protected]

Vida战略合作伙伴（代表ThirtyFiveBio）Tim Brons（媒体）415-675-7402[受电子邮件保护]

SOURCE ThirtyFiveBio

来源ThirtyFiveBio